JW (Cayman) Therapeutics Co. Ltd announced that its board of directors will convene on 27 August 2026. The primary agenda includes:

1. Approval and publication of the unaudited interim results for the six-month period ended 30 June 2026. 2. Discussion of other corporate matters.

Feng Tian, Chairman and Chief Executive Officer, issued the notice from Shanghai on 12 August 2026. The board currently comprises one executive director, two non-executive directors and three independent non-executive directors. No additional operational or financial details were disclosed in the announcement.